Loss of heterozygosity is related to p53 mutations and smoking in lung cancer.

S Zienolddiny, D Ryberg, M O Arab, V Skaug, A Haugen
Author Information
  1. S Zienolddiny: Department of Toxicology, National Institute of Occupational Health, P.O. Box 8149 Dep., Oslo, N-0033, Norway.

Abstract

Carcinogenesis results from an accumulation of several genetic alterations. Mutations in the p53 gene are frequent and occur at an early stage of lung carcinogenesis. Loss of multiple chromosomal regions is another genetic alteration frequently found in lung tumours. We have examined the association between p53 mutations, loss of heterozygosity (LOH) at frequently deleted loci in lung cancer, and tobacco exposure in 165 tumours from non-small cell lung cancer (NSCLC) patients. A highly significant association between p53 mutations and deletions on 3p, 5q, 9p, 11p and 17p was found. There was also a significant correlation between deletions at these loci. 86% of the tumours with concordant deletion in the 4 most involved loci (3p21, 5q11-13, 9p21 and 17p13) had p53 mutations as compared to only 8% of the tumours without deletions at the corresponding loci (P< 0.0001). Data were also examined in relation to smoking status of the patients and histology of the tumours. The frequency of deletions was significantly higher among smokers as compared to non-smokers. This difference was significant for the 3p21.3 (hMLH1 locus), 3p14.2 (FHIT locus), 5q11-13 (hMSH3 locus) and 9p21 (D9S157 locus). Tumours with deletions at the hMLH1 locus had higher levels of hydrophobic DNA adducts. Deletions were more common in squamous cell carcinomas than in adenocarcinomas. Covariate analysis revealed that histological type and p53 mutations were significant and independent parameters for predicting LOH status at several loci. In the pathogenesis of NSCLC exposure to tobacco carcinogens in addition to clonal selection may be the driving force in these alterations.

References

  1. Cancer Res. 1994 Nov 1;54(21):5652-5 [PMID: 7923212]
  2. Cancer Res. 1998 Dec 1;58(23):5478-83 [PMID: 9850082]
  3. Cancer Res. 1994 Nov 15;54(22):5801-3 [PMID: 7954403]
  4. Cell. 1995 Jul 28;82(2):321-30 [PMID: 7628020]
  5. Cancer Detect Prev. 1995;19(6):503-11 [PMID: 8925519]
  6. Science. 1996 Apr 26;272(5261):557-60 [PMID: 8614807]
  7. Cancer Res. 1996 Jul 15;56(14):3331-7 [PMID: 8764130]
  8. Cancer Res. 1996 Sep 15;56(18):4103-7 [PMID: 8797573]
  9. Science. 1996 Oct 18;274(5286):430-2 [PMID: 8832894]
  10. Hum Mol Genet. 1996;5 Spec No:1489-94 [PMID: 8875255]
  11. Carcinogenesis. 1996 Oct;17(10):2201-5 [PMID: 8895489]
  12. Cancer Res. 1997 Jan 15;57(2):206-8 [PMID: 9000555]
  13. Cancer Res. 1997 Mar 15;57(6):1188-93 [PMID: 9067291]
  14. Cancer Res. 1997 Apr 1;57(7):1344-52 [PMID: 9102223]
  15. Nature. 1997 Apr 10;386(6625):623-7 [PMID: 9121588]
  16. Cancer Epidemiol Biomarkers Prev. 1997 May;6(5):315-9 [PMID: 9149890]
  17. Oncogene. 1997 Apr 17;14(15):1847-57 [PMID: 9150391]
  18. Cancer Res. 1997 Jun 1;57(11):2121-3 [PMID: 9187107]
  19. Cancer Res. 1997 Aug 1;57(15):3154-8 [PMID: 9242443]
  20. Nucleic Acids Res. 1997 Oct 1;25(19):3868-74 [PMID: 9380510]
  21. Cancer Metastasis Rev. 1997 Sep-Dec;16(3-4):295-307 [PMID: 9433641]
  22. Oncogene. 1998 Jan 22;16(3):321-6 [PMID: 9467957]
  23. Cancer Res. 1998 Feb 15;58(4):767-78 [PMID: 9485033]
  24. Cancer Res. 1998 Apr 15;58(8):1605-8 [PMID: 9563468]
  25. Cancer Epidemiol Biomarkers Prev. 1998 Apr;7(4):309-14 [PMID: 9568786]
  26. Cancer Res. 1998 May 1;58(9):1804-7 [PMID: 9581816]
  27. Cancer Res. 1998 Jun 15;58(12):2533-6 [PMID: 9635574]
  28. Br J Cancer. 1998 May;77(10):1568-72 [PMID: 9635830]
  29. Int J Cancer. 1998 Jul 17;77(2):173-80 [PMID: 9650548]
  30. Br J Cancer. 1998 Jul;78(1):73-8 [PMID: 9662254]
  31. Oncogene. 1998 Jun 11;16(23):3083-6 [PMID: 9662341]
  32. Int J Cancer. 1998 Nov 23;78(5):606-9 [PMID: 9808530]
  33. Oncogene. 1999 Jan 7;18(1):211-8 [PMID: 9926936]
  34. Oncogene. 1999 Jan 21;18(3):643-50 [PMID: 9989814]
  35. Cancer. 1999 Jan 15;85(2):341-7 [PMID: 10023701]
  36. Br J Cancer. 1999 Mar;79(7-8):1012-7 [PMID: 10098729]
  37. Cancer Res. 1999 Jul 15;59(14):3317-20 [PMID: 10416585]
  38. Carcinogenesis. 1999 Aug;20(8):1403-10 [PMID: 10426784]
  39. Int J Mol Med. 1999 Oct;4(4):419-24 [PMID: 10493985]
  40. Cancer Res. 1993 Oct 15;53(20):4817-22 [PMID: 8402667]
  41. Anticancer Res. 1999 Nov-Dec;19(6C):5523-7 [PMID: 10697610]
  42. Clin Cancer Res. 2000 Mar;6(3):1031-7 [PMID: 10741731]
  43. Cell. 1992 Sep 18;70(6):923-35 [PMID: 1356076]
  44. Cell. 1992 Sep 18;70(6):937-48 [PMID: 1525830]
  45. Cell. 1992 Nov 13;71(4):543-6 [PMID: 1423612]
  46. Cancer Res. 1993 Jan 1;53(1):1-4 [PMID: 8380124]
  47. Clin Cancer Res. 1996 Jul;2(7):1185-9 [PMID: 9816286]
  48. Cancer Res. 1994 Mar 15;54(6):1551-5 [PMID: 8137262]
  49. Anticancer Res. 1994 Jan-Feb;14(1B):261-7 [PMID: 8166465]
  50. Cancer Res. 1994 Sep 15;54(18):4855-78 [PMID: 8069852]
  51. Nucleic Acids Res. 1994 Sep;22(17):3551-5 [PMID: 7937055]

MeSH Term

Adaptor Proteins, Signal Transducing
Adenocarcinoma
Carcinoma, Non-Small-Cell Lung
Carcinoma, Squamous Cell
Carrier Proteins
DNA Adducts
DNA, Neoplasm
DNA-Binding Proteins
Female
Humans
Loss of Heterozygosity
Lung Neoplasms
Male
Microsatellite Repeats
Middle Aged
Multidrug Resistance-Associated Proteins
MutL Protein Homolog 1
MutS Homolog 3 Protein
Mutation
Neoplasm Proteins
Nuclear Proteins
Polymorphism, Single-Stranded Conformational
Smoking
Tumor Suppressor Protein p53

Chemicals

Adaptor Proteins, Signal Transducing
Carrier Proteins
DNA Adducts
DNA, Neoplasm
DNA-Binding Proteins
MLH1 protein, human
MSH3 protein, human
Multidrug Resistance-Associated Proteins
MutS Homolog 3 Protein
Neoplasm Proteins
Nuclear Proteins
Tumor Suppressor Protein p53
MutL Protein Homolog 1
multidrug resistance-associated protein 1

Word Cloud

Created with Highcharts 10.0.0p53lungtumoursmutationslocideletionslocussignificantcancerseveralgeneticalterationsLossfrequentlyfoundexaminedassociationheterozygosityLOHtobaccoexposurecellNSCLCpatientsalso3p215q11-139p21comparedsmokingstatushigherhMLH1CarcinogenesisresultsaccumulationMutationsgenefrequentoccurearlystagecarcinogenesismultiplechromosomalregionsanotheralterationlossdeleted165non-smallhighly3p5q9p11p17pcorrelation86%concordantdeletion4involved17p138%withoutcorrespondingP<00001Datarelationhistologyfrequencysignificantlyamongsmokersnon-smokersdifference33p142FHIThMSH3D9S157TumourslevelshydrophobicDNAadductsDeletionscommonsquamouscarcinomasadenocarcinomasCovariateanalysisrevealedhistologicaltypeindependentparameterspredictingpathogenesiscarcinogensadditionclonalselectionmaydrivingforcerelated

Similar Articles

Cited By